The science was never the hard part.

If you did not have eleven hours this quarter to sit with the people who build, fund, and secure this industry, here is the quarter in one sitting. Nineteen operators. Eleven conversations. Thirteen pages. Free.

Inside this edition

Access. Getting it to a patient. Six conversations.
Capital. Funding it. Three conversations.
Security. Trusting what it is built on. Two conversations.

Karla Loken · Jesús Zurdo · Sunitha Malepati · Craig Lipset · Jim Kremidas · Elisa Cascade · Tom Whitehead · Tori Lee · Steven McWilliams · Richard Hicks · Mike Goguen · Rob Williamson · Edwin Stone · Erik Digman Wiklund · Ali Pashazadeh · Jon Rees · Clinton West · Mike Walker · Theresa Campobasso

Nineteen life-sciences operators, on the record, distilled by Lori Ellis, host of Open Door Salon.

New conversation every week

Before you go, watch this one.

▶

The Best Companies Start in the Worst Times

Mike Goguen spent 20 years as a general partner at Sequoia Capital before founding Two Bear Capital. He sits down with Rob Williamson, CEO of Traverse Therapeutics, on why the strongest companies get built in the worst markets, how to tell real AI in drug discovery from marketing language, and what capital efficiency actually demands when funding dries up. A candid read on building biotech through a downturn from one of venture’s most experienced investors and a founder using AI to cross the blood-brain barrier.

Watch on Open Door Salon →

The science was never the hard part.

Before you go, watch this one.

The Best Companies Start in the Worst Times

Your briefing is on its way.

The Best Companies Start in the Worst Times

JOIN THE CONVERSATION

The Salon

Need the life-sciences signal but short on time?